Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Corcept Therapeutics Korlym (mifepristone) 300mg tablets as a once-daily oral medicine to treat Cushing's syndrome patients.
Subscribe to our email newsletter
Korlym controls hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.
Corcept CEO Joseph Belanoff said they plan to make Korlym available to patients by May 1 through a distribution system designed to support both patients and prescribers.
"We appreciate the FDA’s diligent attention to our NDA and its grant of approval on the PDUFA date," Belanoff added.